Bevacizumab as a monoclonal antibody inhibits mitochondrial complex II in isolated rat heart mitochondria: ameliorative effect of ellagic acid

References

• Arbeláez, L.F.G., et al., 2018. Cardioprotection and natural polyphenols: an update of clinical and experimental studies. Food & Function, 9, 6129–6145.
   PubMed Web of Science ®Google Scholar
• Bordun, K.A., et al., 2015. The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab-and sunitinib-mediated cardiotoxicity. American Journal of Physiology-Heart and Circulatory Physiology, 309 (4), H692–H701.
   PubMed Web of Science ®Google Scholar
• Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72 (1–2), 248–254.
   PubMed Web of Science ®Google Scholar
• Chen, P., Chen, F., and Zhou, B., 2018. Antioxidative, anti-inflammatory and anti-apoptotic effects of ellagic acid in liver and brain of rats treated by D-galactose. Scientific Reports, 8 (1), 1465.
   PubMed Web of Science ®Google Scholar
• Chu, T.F., et al., 2007. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet, 370 (9604), 2011–2019.
   PubMed Web of Science ®Google Scholar
• Commisso, C., et al., 2013. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature, 497 (7451), 633–637.
   PubMed Web of Science ®Google Scholar
• Curigliano, G., et al., 2016. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA: A Cancer Journal for Clinicians, 66, 309–325.
   PubMed Web of Science ®Google Scholar
• Deavall, D.G., et al., 2012. Drug-induced oxidative stress and toxicity. Journal of Toxicology, 2012, 1–13.
   Google Scholar
• Deissler, H.L., Lang, G.K., and Lang, G.E., 2016. Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: evidence for an involvement of the neonatal Fc receptor. Experimental Eye Research, 143, 49–59.
   PubMed Web of Science ®Google Scholar
• Economopoulou, P., et al., 2015. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Management and Research, 7, 133–143.
   PubMed Web of Science ®Google Scholar
• Eruslanov, E. and Kusmartsev, S., 2010. Identification of ROS using oxidized DCFDA and flow-cytometry. In: D. Armstrong, ed. Advanced protocols in oxidative stress II. Totowa, NJ: Humana Press, 57–72.
   Google Scholar
• Gerencser, A.A., et al., 2008. Mitochondrial swelling measurement in situ by optimized spatial filtering: astrocyte-neuron differences. Biophysical Journal, 95 (5), 2583–2598.
   PubMed Web of Science ®Google Scholar
• Gorini, S., et al., 2018. Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxidative Medicine and Cellular Longevity, 2018, 1–15.
   Web of Science ®Google Scholar
• Guo, D., et al., 2017. VEGF stimulated the angiogenesis by promoting the mitochondrial functions. Oncotarget, 8, 77020.
   PubMedGoogle Scholar
• Hemmati, A., et al., 2018. Ellagic acid protects against arsenic trioxide–induced cardiotoxicity in rat. Human & Experimental Toxicology, 37, 412–419.
   PubMed Web of Science ®Google Scholar
• Hosseini, M.J., et al., 2013. Toxicity of cigarette smoke on isolated lung, heart, and brain mitochondria: induction of oxidative stress and cytochrome c release. Toxicological & Environmental Chemistry, 95, 1624–1637.
   Web of Science ®Google Scholar
• Incalza, M.A., et al., 2018. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascular Pharmacology, 100, 1–19.
   PubMed Web of Science ®Google Scholar
• Jain, D., et al., 2017. Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment. Annals of Translational Medicine, 5 (17), 348–348.
   PubMed Web of Science ®Google Scholar
• Kang, Y.J., 2001. Molecular and cellular mechanisms of cardiotoxicity. Environmental Health Perspectives, 109, 27–34.
   PubMed Web of Science ®Google Scholar
• Kerbel, R.S., 2006. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science, 312 (5777), 1171–1175.
   PubMed Web of Science ®Google Scholar
• Keshtzar, E., et al., 2016. Ellagic acid protects against arsenic toxicity in isolated rat mitochondria possibly through the maintaining of complex II. Human & Experimental Toxicology, 35, 1060–1072.
   PubMed Web of Science ®Google Scholar
• Kuznetsov, A.V., et al., 2011. Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. Biochimica et Biophysica Acta (Bba) - Molecular Cell Research, 1813 (6), 1144–1152.
   PubMed Web of Science ®Google Scholar
• Laplante, M. and Sabatini, D.M., 2012. mTOR signaling in growth control and disease. Cell, 149 (2), 274–293.
   PubMed Web of Science ®Google Scholar
• Lim, J.P. and Gleeson, P.A., 2011. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunology and Cell Biology, 89 (8), 836–843.
   PubMed Web of Science ®Google Scholar
• Liu, Y., et al., 1997. Mechanism of cellular 3‐(4, 5‐dimethylthiazol‐2‐yl)‐2, 5‐diphenyltetrazolium bromide (MTT) reduction. Journal of Neurochemistry, 69 (2), 581–593.
   PubMed Web of Science ®Google Scholar
• Luthra, S., et al., 2013. Effect of bevacizumab (Avastin™) on mitochondrial function of in vitro retinal pigment epithelial, neurosensory retinal and microvascular endothelial cells. Indian Journal of Ophthalmology, 61, 705.
   PubMed Web of Science ®Google Scholar
• Madonna, R., et al., 2015. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Failure Reviews, 20 (5), 621–631.
   PubMed Web of Science ®Google Scholar
• Müller-Greven, G., et al., 2017. Macropinocytosis of Bevacizumab by Glioblastoma cells in the perivascular niche affects their survival. Clinical Cancer Research, 23 (22), 7059–7071.
   PubMed Web of Science ®Google Scholar
• Nanegrungsunk, D., et al., 2016. Bevacizumab is superior to Temozolomide in causing mitochondrial dysfunction in human brain tumors. Neurological Research, 38 (4), 285–293.
   PubMed Web of Science ®Google Scholar
• O’Connor, J.E., et al., 1988. Use of rhodamine 123 to investigate alterations in mitochondrial activity in isolated mouse liver mitochondria. Biochemical and Biophysical Research Communications, 151, 568–573.
   PubMed Web of Science ®Google Scholar
• Odinokova, I., et al., 2018. Effect of melatonin on rat heart mitochondria in acute heart failure in aged rats. International Journal of Molecular Sciences, 19 (6), 1555.
   PubMed Web of Science ®Google Scholar
• Ooi, B.K., et al., 2018. The role of natural products in targeting cardiovascular diseases via Nrf2 pathway: novel molecular mechanisms and therapeutic approaches. Frontiers in Pharmacology, 9, 1308.
   PubMed Web of Science ®Google Scholar
• Pereira, C.V., et al., 2009. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety? Current Drug Safety, 4 (1), 34–54.
   PubMedGoogle Scholar
• Ramakrishnan, S., Anand, V., and Roy, S., 2014. Vascular endothelial growth factor signaling in hypoxia and inflammation. Journal of Neuroimmune Pharmacology, 9 (2), 142–160.
   PubMed Web of Science ®Google Scholar
• Rana, P., et al., 2019. Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs. Chemical Research in Toxicology, 32 (1), 156–167.
   PubMed Web of Science ®Google Scholar
• Salimi, A., et al., 2015. Ellagic acid, a polyphenolic compound, selectively induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL patients by directly targeting mitochondria. Redox Biology, 6, 461–471.
   PubMed Web of Science ®Google Scholar
• Schmidinger, M., et al., 2007. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 26, 5204–5212.
   Google Scholar
• Scialò, F., Fernández-Ayala, D.J., and Sanz, A., 2017. Role of mitochondrial reverse electron transport in ROS signaling: potential roles in health and disease. Frontiers in Physiology, 8, 428.
   PubMed Web of Science ®Google Scholar
• Spinazzi, M., et al., 2012. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nature Protocols, 7 (6), 1235–1246.
   PubMed Web of Science ®Google Scholar
• Touyz, R.M. and Herrmann, J., 2018. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precision Oncology, 2 (1), 13.
   PubMed Web of Science ®Google Scholar
• Varga, Z.V., et al., 2015. Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology-Heart and Circulatory Physiology, 309 (9), H1453–H1467.
   PubMed Web of Science ®Google Scholar
• Warpe, V.S., et al., 2015. Cardioprotective effect of ellagic acid on doxorubicin induced cardiotoxicity in wistar rats. Journal of Acute Medicine, 5 (1), 1–8.
   Web of Science ®Google Scholar
• Yu, J., et al., 2018. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Phytomedicine, 40, 125–139.
   PubMed Web of Science ®Google Scholar
• Zhao, R.Z., et al., 2019. Mitochondrial electron transport chain, ROS generation and uncoupling. International Journal of Molecular Medicine, 44, 3–15.
   PubMed Web of Science ®Google Scholar
• Zorov, D.B., Juhaszova, M., and Sollott, S.J., 2014. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiological Reviews, 94 (3), 909–950.
   PubMed Web of Science ®Google Scholar